These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 21456064

  • 1. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.
    Abedinpour P, Baron VT, Welsh J, Borgström P.
    Prostate; 2011 Jun 01; 71(8):813-23. PubMed ID: 21456064
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
    Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, Shih WJ, Huang MT, Liu Y, Rabson A, Reddy B, Yang CS, Conney AH.
    Cancer Prev Res (Phila); 2010 Jan 01; 3(1):114-24. PubMed ID: 20051379
    [Abstract] [Full Text] [Related]

  • 3. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
    Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D.
    Clin Cancer Res; 2004 Dec 15; 10(24):8728-34. PubMed ID: 15623658
    [Abstract] [Full Text] [Related]

  • 4. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 5. The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo.
    Abedinpour P, Baron VT, Chrastina A, Welsh J, Borgström P.
    Prostate; 2013 Apr 15; 73(5):489-99. PubMed ID: 22996809
    [Abstract] [Full Text] [Related]

  • 6. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA, Narayanan NK, Pittman B, Reddy BS.
    Clin Cancer Res; 2004 Nov 15; 10(22):7727-37. PubMed ID: 15570007
    [Abstract] [Full Text] [Related]

  • 7. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H.
    Cancer Res; 2004 May 01; 64(9):3334-43. PubMed ID: 15126378
    [Abstract] [Full Text] [Related]

  • 8. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C.
    Int J Cancer; 2008 Jul 01; 123(1):195-201. PubMed ID: 18386814
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC.
    Int J Radiat Oncol Biol Phys; 2007 Mar 01; 67(3):888-96. PubMed ID: 17293239
    [Abstract] [Full Text] [Related]

  • 10. COX-2 inhibitors in prostate cancer treatment--hold your horses?
    Cheung AS, Grossmann M.
    Asian J Androl; 2012 Jul 01; 14(4):518-9. PubMed ID: 22635163
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
    Wang H, Cui XX, Goodin S, Ding N, Van Doren J, Du Z, Huang MT, Liu Y, Cheng X, Dipaola RS, Conney AH, Zheng X.
    Oncol Rep; 2014 Feb 01; 31(2):835-41. PubMed ID: 24296978
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K.
    Cancer; 1999 Apr 15; 85(8):1822-7. PubMed ID: 10223578
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
    Klenke FM, Abdollahi A, Bischof M, Gebhard MM, Ewerbeck V, Huber PE, Sckell A.
    Strahlenther Onkol; 2011 Jan 15; 187(1):45-51. PubMed ID: 21234531
    [Abstract] [Full Text] [Related]

  • 19. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
    Wang L, Chen W, Xie X, He Y, Bai X.
    Exp Oncol; 2008 Mar 15; 30(1):42-51. PubMed ID: 18438340
    [Abstract] [Full Text] [Related]

  • 20. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM, Kido LA, Silva RS, Cagnon VHA, Montico F.
    Prostate; 2019 Apr 15; 79(5):515-535. PubMed ID: 30585351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.